Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
HILS

HILS - Hillstream BioPharma, Inc. Stock Price, Fair Value and News

$2260.000.00 (0.00%)
Market Closed

8/100

HILS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

8/100

HILS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1876

Target 3M

$2110.5

Target 6M

$1993.25

HILS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HILS Price Action

Last 7 days

0.4%

Last 30 days

4.2%

Last 90 days

4.6%

HILS RSI Chart

HILS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HILS Valuation

Market Cap

79.2B

Price/Earnings (Trailing)

-7.7K

Price/Sales (Trailing)

1.8M

Price/Free Cashflow

-9.1K

HILS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1876

Target 3M

$2110.5

Target 6M

$1993.25

HILS Fundamentals

HILS Revenue

Revenue (TTM)

44.7K

Rev. Growth (Yr)

-98.09%

Rev. Growth (Qtr)

-35.98%

HILS Earnings

Earnings (TTM)

-10.3M

Earnings Growth (Yr)

44.63%

Earnings Growth (Qtr)

-13.3%

HILS Profitability

Return on Equity

-167.66%

Return on Assets

-134.03%

Free Cashflow Yield

-0.01%

HILS Investor Care

Shares Dilution (1Y)

2258.27%

Diluted EPS (TTM)

-3.97

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025167.4K116.0K44.7K0
2024216.3K235.7K280.0K249.9K
2023000152.6K
Get all data in R, Python etc through our Historical Stock Data APIs

About Hillstream BioPharma, Inc.

HILS
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.
 CEO
 WEBSITEhillstreambio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES1

Hillstream BioPharma, Inc. Frequently Asked Questions

HILS is the stock ticker symbol of Hillstream BioPharma, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Hillstream BioPharma, Inc. is 79.2 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check HILS's fair value in chart for subscribers.

The fair value guage provides a quick view whether HILS is over valued or under valued. Whether Hillstream BioPharma, Inc. is cheap or expensive depends on the assumptions which impact Hillstream BioPharma, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HILS.

As of Wed Jan 28 2026, HILS's PE ratio (Price to Earnings) is -7675.1 and Price to Sales (PS) ratio is 1.77 Million. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HILS PE ratio will change depending on the future growth rate expectations of investors.